🔗 Share this article

While America undertakes sweeping revisions to its vaccination guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccinations during the global health crisis and has focused upon possible fatalities following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Health officials planned to reveal radical revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of step with a large portion of the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

Instead of Vinay Prasad, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for halting specific pediatric shot schedules in the US to become more in line with the Danish model, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – typically the domain of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Background

The appointee has little discernible background in drug development, regulation or management, which has been typical for previous heads of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

The drug center has an vast portfolio at the agency, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears numerous generic drugs. There’s a biosimilars division, over-the-counter program and so forth, and all of those have to be managed,” Dr. Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant administrative aspect to the job, which manages more than 5,000 personnel. “It’s a massive management job, if you execute it properly,” she concluded.

Official Statement and Disputed Policies

When asked about concerns about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among agency officials on vaccines, a representative responded that the “inquiries stem from flawed presumptions”.

“Her resume is consistent with the responsibilities of her job,” the spokesperson explained, noting the months Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that allegedly concerned her preceding directors. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Howard asked. “There is a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Documented Track Record on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, history, some experts have noted. She published a analysis using non-validated crowd-sourced reports to estimate the frequency of heart inflammation after COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the current government included altering rules for recently developed shots and halting “unnecessary” immunizations, she said following the vote on a online show. At the FDA, Dr. Høeg has reportedly proposed preventing adolescent males from getting COVID-19 vaccines.

“She’s an complete dogmatist who begins with her preconceived notions and works backwards to fit the evidence in a extremely deceptive, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|